BACKGROUND. Spasticity is a prevalent disabling clinical symptom for children with
cerebral palsy. Treatment of spasticity with botulinum toxin in children with cerebral palsy …

✓ Hypertonicity is a leading cause of disability for children with cerebral palsy (CP).
Botulinum toxin A (BTA) chemically denervates muscle tissue and is commonly used in the …

Botulinum A toxin produces selective and reversible chemodenervation that can be
employed to balance muscle forces across joints in children with cerebral palsy (CP) …

Despite several trials showing reductions in tone and improvements in gait, the relation
between botulinum toxin A (BTX-A) dose and response has rarely been investigated. A …

Botulinum neurotoxin type‐A (BoNT‐A) has been used in association with other
interventions in the management of spasticity in children with cerebral palsy (CP) for almost …

THE JOURNAL OF PEDIATRICS EDITORIALS VOLUME 137, NUMBER 3 indications, and
the expected outcomes are not yet established. When spasticity is severe and generalized …

Intramuscular injections of botulinum toxin type A (BTX-A) have increasingly been used to
reduce spasticity in specific muscle groups in children with cerebral palsy. Targets of …

Question What is the role of intramuscular botulinum toxin injections in the management of
spasticity and related morbidity in children with cerebral palsy? Answer When botulinum …

INTRODUCTION: Cerebral palsy is the most common cause of physical disability in children.
Spasticity is a disabling clinical symptom that is prevalent among patients suffering from …

During the past 25 years, botulinum toxin type A (BoNT-A) has become the most widely used
medical intervention in children with cerebral palsy. In this review we consider the gaps in …